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DMR

:   dynamic mass redistribution

PPHT

:   2‐(N‐Phenethyl‐N‐propyl)amino‐5‐hydroxytetralin

RT

:   room temperature

Introduction {#bph14456-sec-0005}
============

The potential influence of drug‐target association and dissociation kinetics on the time course of drug effects (pharmacodynamics) has led to an increasing interest in the use of binding kinetic parameters as a criterion in the selection of drug candidates (Copeland *et al*., [2006](#bph14456-bib-0009){ref-type="ref"}; Zhang and Monsma, [2010](#bph14456-bib-0057){ref-type="ref"}; Lu and Tonge, [2011](#bph14456-bib-0032){ref-type="ref"}; Dahl and Akerud, [2013](#bph14456-bib-0010){ref-type="ref"}; Copeland, [2016](#bph14456-bib-0008){ref-type="ref"}; Vauquelin, [2016](#bph14456-bib-0051){ref-type="ref"}). Although the influence of binding kinetics on the time course of target occupancy has been studied, its exact role in the complex relation between drug dosing and drug effect is potentially complex and not completely understood (Yin *et al*., [2013](#bph14456-bib-0055){ref-type="ref"}; de Witte *et al*., [2016](#bph14456-bib-0012){ref-type="ref"}).

Under distinct circumstances, target binding kinetics can influence the pharmacodynamics directly by affecting the time course of the target occupancy. To what extent this occurs depends on the rate constant values for target association (k~on~) and dissociation (k~off~), relative to the pharmacokinetic rate constants characterizing the rates of tissue distribution and elimination. In this regard, additional factors to be taken into consideration are the rate constants characterizing the turnover of the target and the competition with endogenous target ligands. In addition to these direct effects of target binding on the pharmacodynamics, variation in k~on~ and k~off~ can also indirectly influence the pharmacodynamics *via* signal transduction and homeostatic feedback mechanisms, both at the cellular and at the systems level (Kleinbloesem *et al*., [1987](#bph14456-bib-0026){ref-type="ref"}; Francheteau *et al*., [1993](#bph14456-bib-0017){ref-type="ref"}; Landersdorfer *et al*., [2012](#bph14456-bib-0029){ref-type="ref"}; Yin *et al*., [2013](#bph14456-bib-0055){ref-type="ref"}; de Witte *et al*., [2016](#bph14456-bib-0012){ref-type="ref"}).

One target for which the influence of drug‐target binding kinetics on *in vivo* drug effects is thought to be relevant is the dopamine <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=215>. Almost two decades ago, the influence of drug‐target binding kinetics on the safety of dopamine D~2~ antagonists has been suggested, based on the correlation between the high values of k~off~ and the lack of typical side effects, such as extrapyramidal symptoms (i.e. atypicality) (Meltzer, [2004](#bph14456-bib-0034){ref-type="ref"}). This observation led to the hypothesis that quickly dissociating antagonists induce less side effects by allowing displacement from the receptor by fluctuating <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940> concentrations and thus preserving part of the dopamine dynamics, which we will refer to as the 'fast‐off hypothesis' in this study (Kapur and Seeman, [2000](#bph14456-bib-0022){ref-type="ref"}, [2001](#bph14456-bib-0023){ref-type="ref"}; Langlois *et al*., [2012](#bph14456-bib-0030){ref-type="ref"}; Vauquelin *et al*., [2012](#bph14456-bib-0052){ref-type="ref"}). These fluctuations in dopamine concentrations occur at various time scales *in vivo*, ranging from hours to microseconds (Young *et al*., [1998](#bph14456-bib-0056){ref-type="ref"}; Schultz, [2007](#bph14456-bib-0044){ref-type="ref"}; Vauquelin *et al*., [2012](#bph14456-bib-0052){ref-type="ref"}).

The dopamine D~2~ receptor belongs to the class of inhibitory GPCRs. Thus, receptor activation is known to inhibit production of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352>, and cAMP in turn is known to stimulate active <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=260> production, while active PDE stimulates degradation of cAMP. Moreover, GPCR receptor activation can lead to receptor phosphorylation and desensitization as described quantitatively for the β~2~‐adrenergic receptor (Violin *et al*., [2008](#bph14456-bib-0053){ref-type="ref"}). The production of cAMP is thus regulated by a negative feedback loop, which is a common feature in signal transduction pathways (Ingalls, [2013](#bph14456-bib-0021){ref-type="ref"}). Many compounds binding to D~2~ receptors that were initially classified as antagonists, were later reported to function as inverse agonists (Hall and Strange, [1997](#bph14456-bib-0019){ref-type="ref"}; Bond and IJzerman, [2006](#bph14456-bib-0004){ref-type="ref"}). For convenience, in this text, only the terms agonist and antagonist will be used.

In the present study, *in vitro* and *in silico* methods were combined to elucidate the influence of D~2~ receptor antagonist target binding kinetics on the cellular response to fluctuating dopamine concentrations and to investigate the fast‐off hypothesis. Firstly, experimental methods were developed to quantify the binding kinetics of D~2~ receptor antagonists, to support the comparison of signal transduction kinetics to target binding kinetics. Secondly, to investigate the fast‐off hypothesis with respect to the competition between antagonists and dopamine, the cellular response kinetics after subsequent exposure to dopamine and D~2~ receptor antagonists with varying binding kinetics at different levels of the signalling pathway were measured. A minimal mechanistic model combining D~2~ receptor binding kinetics, D~2~ receptor turnover, cAMP and active PDE turnover was established to describe cAMP concentration versus time curves in response to D~2~ receptor antagonist exposure. Thirdly, the model was used to identify the role of binding kinetics on drug effect for fluctuating dopamine concentrations. The physiological range of dopamine fluctuation time scales was taken into account by using a frequency response analysis (Ang *et al*., [2011](#bph14456-bib-0003){ref-type="ref"}; Ingalls, [2013](#bph14456-bib-0021){ref-type="ref"}), a method that can be used to increase the kinetic insight into pharmacokinetic and pharmacodynamic model behaviour, as recently demonstrated (Schulthess *et al*., [2017](#bph14456-bib-0043){ref-type="ref"}). For a more general insight in the influence of binding kinetics on signal transduction, this analysis was expanded to a range of hypothetical turnover rates of cAMP and active PDE.

Methods {#bph14456-sec-0006}
=======

This study consists of three parts: *In vitro* measurements of target binding and signal transduction kinetics: drug‐target binding parameters of 17 dopamine D~2~ receptor antagonists were measured at room temperature and at 37°C. The *in vitro* response after dopamine pre‐incubation was measured for two different biomarkers: cAMP concentrations over time as second messenger and dynamic mass redistribution (DMR) as a composite signalling marker.Model‐based analysis of the *in vitro* cAMP antagonist response curves: a minimal mechanistic model was developed to describe the cAMP responses of the antagonists, based on the target binding kinetics as determined in part I.Frequency response analysis: simulations of the predicted *in vivo* response to fluctuating dopamine concentrations. The mechanistic model was used to simulate the cAMP response to dopamine concentrations that fluctuate according to a sine‐wave pattern with a range of physiologically relevant frequencies between 2\*10^−6^ min^−1^ and 7 min^−1^. The fluctuation amplitude of cAMP, compared to dopamine, was used to summarize the cAMP response.

*In vitro* measurements of target binding and signal transduction kinetics {#bph14456-sec-0007}
--------------------------------------------------------------------------

### Equilibrium and kinetic probe competition assay (ePCA and kPCA) {#bph14456-sec-0008}

Affinity and kinetic binding parameters for the 17 studied antagonists (see Table [1](#bph14456-tbl-0001){ref-type="table"}) were measured with a homogeneous time‐resolved fluorescence energy transfer (TR‐FRET) binding competition method as previously described for the histamine H1 and the GnRH receptors (Schiele *et al*., [2014](#bph14456-bib-0041){ref-type="ref"}; Nederpelt *et al*., [2016](#bph14456-bib-0036){ref-type="ref"}). In this study, Tag‐lite^®^ dopamine D~2~‐labelled cells and a poly‐3‐phenylhydrazone thiophene (PPHT)‐based dopamine D~2~ receptor red agonist fluorescent ligand (both from Cisbio, Codolet, France) were used as receptor‐tracer pair to be competed with unlabelled test compounds \[Tocris Bioscience (Abingdon, UK), TRC, Sigma‐Aldrich (St. Louis, MO, USA), Biotrend Chemicals AG (Köln, Germany) or provided by Janssen Pharmaceutica (Beerse Belgium)\]. Briefly, frozen cells containing the terbium (Tb^2+^) labelled D~2~ receptor, were thawed, spun down and re‐suspended in Tag‐lite buffer (Cisbio) to the concentration indicated by the manufacturer and dispensed into Greiner black small volume 384‐well microtiter plates already containing the fluorescent tracer (10 nM end concentration) and the antagonists. These compounds were diluted and transferred to the test plates following the procedures described previously (Schiele *et al*., [2014](#bph14456-bib-0041){ref-type="ref"}).

###### 

Kinetic and affinity parameters (k~on~, k~off~ and K~D~) for the D~2~ receptor antagonists used to develop the models presented in this study

  Compound ID        \#   K~D~ \[M\]   SD         k~on~ \[1/(M\*s)\]   SD           k~off~ \[1/s\]   SD
  ------------------ ---- ------------ ---------- -------------------- ------------ ---------------- ----------
  (‐)‐Nemonapride    1    9.58E‐11     3.26E‐12   5.66E + 06           2.73E + 05   5.43E‐04         4.46E‐05
  Bromperidol        2    1.89E‐09     7.49E‐10   2.26E + 06           9.57E + 05   3.91E‐03         1.21E‐04
  Clozapine          3    5.05E‐08     1.28E‐08   1.20E + 06           1.44E + 06   5.13E‐02         5.74E‐02
  Domperidone        4    3.04E‐09     5.08E‐10   1.81E + 05           5.26E + 04   5.37E‐04         6.75E‐05
  Dopamine           5    1.27E‐06     5.56E‐07   1.88E + 04           2.16E + 04   2.82E‐02         3.01E‐02
  JNJ‐37822681       6    9.32E‐09     2.71E‐09   7.33E + 05           NA           9.54E‐03         NA
  JNJ‐39269646       7    4.87E‐08     8.35E‐09   4.53E + 06           4.51E + 06   1.79E‐01         1.64E‐01
  Haloperidol        8    3.82E‐10     4.98E‐11   1.21E + 07           5.18E + 06   4.48E‐03         1.37E‐03
  Olanzapine         9    8.58E‐09     3.38E‐09   \>7.30E + 05         NA           \>1.00E‐02       NA
  Paliperidone       10   5.45E‐09     2.07E‐09   6.81E + 05           1.83E + 05   3.52E‐03         4.14E‐04
  Pimozide           11   2.55E‐10     6.74E‐11   3.10E + 05           2.45E + 05   7.08E‐05         4.17E‐05
  Quetiapine         12   1.50E‐07     6.94E‐08   1.03E + 05           2.04E + 04   1.69E‐02         6.07E‐03
  Remoxipride        13   8.31E‐08     3.47E‐08   3.28E + 05           NA           3.14E‐02         NA
  Risperidone        14   7.56E‐10     7.62E‐11   4.43E + 06           8.54E + 05   3.31E‐03         3.09E‐04
  Sertindole         15   4.07E‐09     2.23E‐09   7.70E + 05           7.00E + 05   2.35E‐03         1.13E‐03
  Spiperone          16   1.79E‐10     4.11E‐12   5.44E + 06           1.11E + 06   9.70E‐04         1.76E‐04
  S‐(+)‐Raclopride   17   6.34E‐10     1.15E‐10   9.57E + 05           1.81E + 05   5.96E‐04         4.62E‐06
  Ziprasidone        18   1.31E‐09     8.40E‐11   1.29E + 06           2.01E + 05   1.67E‐03         1.55E‐04

Data is the average of two kPCA measurements (*N* = 2, *n* = 2) at room temperature. NA, not available

Starting concentrations of the D~2~ receptor antagonist dilution series were adapted according to their expected affinity, in order to cover a meaningful dose range (see Supporting Information Figure [S1](#bph14456-supitem-0001){ref-type="supplementary-material"}). At least two independent ePCA and kPCA experiments with two replicates each (*N* = 2, *n* = 2) as described above were performed at room temperature and 37°C. For steady state assays, plates were kept in standard tissue culture incubators, whereas for kinetic assays, the temperature control function of the PHERAstar FS™ microtiter plate reader was used. For ePCA, tracer and D~2~ receptor‐labelled cells were dispensed to the ready‐to‐use compound plates to a final volume of 5 μL, and the mixture was incubated for 1 to 2 h prior to acquisition of the steady state TR‐FRET ratiometric signals (665/620 nm) upon excitation at 337 nm. Normalized values were fitted to a logistic four‐parameter model using the Genedata Screener™ software, and K~i~ values calculated using the Cheng--Prusoff relationship (Cheng and Prusoff, [1973](#bph14456-bib-0006){ref-type="ref"}). For kPCA, the tracer was dispensed to the ready‐to‐use compound plates prior to introducing them into the PHERAstar FS microtiter plate reader. Then the D~2~ receptor‐labelled cells were added to wells to a final volume of 10 μL using the injector system of the instrument, and kinetic TR‐FRET readings were made at time zero and every 21 s or 100 s (depending on whether faster or slower compounds were being measured) for the times indicated in Supporting Information Figure [S1](#bph14456-supitem-0001){ref-type="supplementary-material"}. Baseline‐normalized kinetic traces were analysed with a competitive binding kinetics model (Motulsky and Mahan, [1984](#bph14456-bib-0035){ref-type="ref"}) adapted to deal with normalized‐ instead of blank‐subtracted curves using the Genedata Screener software. Prior to D~2~ antagonist testing, binding saturation and kinetic association and dissociation curves for the dopamine D~2~ receptor red antagonist fluorescent ligand were recorded (*N* = 2, *n* = 3) as previously described (Schiele *et al*., [2014](#bph14456-bib-0041){ref-type="ref"}; Nederpelt *et al*., [2016](#bph14456-bib-0036){ref-type="ref"}). Subsequently, these curves were fitted to the corresponding models using GraphPad Prism™ in order to obtain the affinity and kinetic constants used as input parameters in the Cheng--Prusoff and Motulsky and Mahan models for Supporting Information Figure [S1](#bph14456-supitem-0001){ref-type="supplementary-material"}a (Cheng and Prusoff, [1973](#bph14456-bib-0006){ref-type="ref"}).

### cAMP assay {#bph14456-sec-0009}

CHO/hD~2~ and wt‐CHO cells were grown in DMEM/F12 with glutamine (without phenol red; Gibco, Dublin, Ireland), 1% heat inactivated FCS, 1× penicillin/streptomycin, 400 μg·mL^−1^ G418. Cells were cultured in humidified atmosphere at 37°C and 5% CO~2~ in air.

To gain insight in the activity of known antagonists after binding to the D~2~ receptor, changes in the cellular cAMP level were analysed. To allow real time kinetic measurement, a cAMP‐biosensor variant pGloSensor™‐22F (Promega Corporation) was used, which consists of a cAMP binding domain (cAMP binding domain B from human PKA regulatory subunit type II β) fused to mutant luciferase. Binding of cAMP results in a conformational change and an increase in luminescence signal. The use of the biosensor system provides a method for a real time measurement of changes in the cAMP level in a non‐lytic assay format. Cells from a CHO cell line (CHO, RRID:CVCL_VL22) stably transfected with the long isoform of the human dopamine D~2~ receptor, CHO/hD~2~ cells, were kindly provided by Janssen Pharmaceutica.

CHO/hD~2~ cells (15 000/50 μL) were transiently transfected with the pGloSensor‐22F plasmid (2 ng·μL^−1^ i.a.) using FuGeneHD transfection reagent (3 μL FuGeneHD: 1 μg DNA plasmid, Promega, Madison, USA). By reaching 70--80% confluency, cells were harvested using Trypsin/EDTA and resuspended in DMEM/F‐12/HEPES medium supplemented with 1% fetal calf serum (FCS), pen/strep and 1 mg·mL^−1^ G418. Prior to addition of the pGloSensor‐22F plasmid to cells, it was incubated for 20 min with the FuGeneHD transfection reagent at room temperature. By the end of incubation time, the cells and transfection solution were combined, mixed and plated in white, solid bottom 384‐well assay plates (Greiner CELLSTAR^®^ 384‐well plates). After 24 h of incubation, the transfection mixture was replaced by 20 μL per well DMEM/F‐12/HEPES medium with 9% Glo‐substrate followed by 2 h incubation at room temperature. To achieve a good signal window, CHO/hD~2~ cells were treated with 3 μM <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5190> for 30 min. Forskolin was used as an activator of the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=257#1279> and therefore for a receptor‐independent increase of the cellular cAMP level. In order to monitor antagonist activity against the natural receptor ligand, cells were incubated with 15 nM dopamine for 20 min prior to addition of antagonists. D~2~‐receptor antagonists were tested in a 10‐point dose response (top concentration 10 μM, 1:4 dilutions), and each condition was measured in triplicate. Signal kinetics was detected for a total period of 1 h every 2 min. All compounds were dissolved in DMSO (Carl Roth GmbH + Co. K, Karlsruhe, Germany).

### Dynamic mass redistribution (DMR) assay {#bph14456-sec-0010}

For DMR measurements (Fang *et al*., [2008](#bph14456-bib-0015){ref-type="ref"}), 10 μL per well cell culture media (DMEM/F12 without phenol red, Gibco) were transferred into an EnSpire‐LFC 384-- fibronectin coated plate (PerkinElmer, Waltham, USA) and incubated for 30 min. A suspension of CHO/hD~2~ cells in cell culture media was prepared, and cells were seeded into the label‐free cellular (LFC) plate (1.5 × 10^4^ cells per well), resulting in a final volume of 30 μL per well. The LFC plate was incubated overnight in a humidified atmosphere at 37°C and 5% CO~2~ in air.

On the next day, label‐free assay buffer (HBSS, Sigma Aldrich, St Louis, MO), 20 mM HEPES (Sigma Aldrich), 0.5% (v/v) DMSO, 0.05% v/v Pluronic (AnaSpec, Fremont, CA, USA) was prepared. Dopamine was diluted in a label‐free assay buffer (5 uM, final assay concentration) and dispensed into an intermediate plate (polypropylene 384‐well microplate; Greiner Bio‐One GmbH, Frickenhausen, Germany). Of each antagonist, a dilution series in DMSO was prepared and transferred into an intermediate plate. Label‐free assay buffer was added to the intermediate plate to dilute the antagonists further.

The media was removed from the LFC plate by washing the wells four times with label‐free assay buffer (25 μL per well). The total assay volume after the washing step was 30 μL per well. The LFC plate was placed in an EnSpire multimode reader equipped with Corning^®^ Epic^®^ label‐free technology (PerkinElmer). After 2 h, a baseline was recorded (10 min) followed by the addition of dopamine or vehicle control (10 μL per well) from the intermediate plate. Antagonist dispensing and mixing were automated using a Janus Workstation (PerkinElmer). A 20 min kinetic DMR measurement was recorded on the EnSpire multimode reader. Directly afterwards, the D~2~‐receptor antagonists were transferred from the intermediate plate to the LFC plate (10 μL per well), and a 90 min kinetic DMR measurement was initiated on the EnSpire multimode reader.

Model‐based analysis of the *in vitro* cAMP antagonist response curves {#bph14456-sec-0011}
----------------------------------------------------------------------

### Modelling procedure {#bph14456-sec-0012}

To obtain a detectable cAMP signal, AC was activated first by forskolin. The dynamics of this activation was recorded in a separate experiment. As the cAMP response to forskolin addition was measured separately from the cAMP response to the D~2~‐receptor antagonists, the D~2~ antagonist response measurements were normalized to the average cAMP response before antagonist addition (baseline). A mechanistic model, based on previous models and mechanistic information from literature (Spence *et al*., [1995](#bph14456-bib-0048){ref-type="ref"}; Hall and Strange, [1997](#bph14456-bib-0019){ref-type="ref"}; de Ligt *et al*., [2000](#bph14456-bib-0011){ref-type="ref"}; Cherry and Pho, [2002](#bph14456-bib-0007){ref-type="ref"}; Bond and IJzerman, [2006](#bph14456-bib-0004){ref-type="ref"}; Violin *et al*., [2008](#bph14456-bib-0053){ref-type="ref"}; Keravis and Lugnier, [2012](#bph14456-bib-0024){ref-type="ref"}), combining dopamine‐receptor binding kinetics, antagonist‐receptor binding kinetics and cAMP as well as active PDE turnover to describe the generation of the cAMP response, was used to simultaneously fit the cAMP data of all antagonists. A diversity of models, with differences in mechanistic detail (Table [2](#bph14456-tbl-0002){ref-type="table"}), was tested for their utility to describe the cAMP responses. Model fitting was performed in NONMEM v7.3 using ADVAN9. All values of k~off~, including the k~off~ of dopamine, were fixed to the values that were measured according to the methods described above, while the K~D~ values were estimated. Models were selected based on the objective function value (OFV), visual inspection of the individual fits of the experiments and physiological plausibility of the models. The OFV is calculated as −2\* the natural logarithm of the likelihood, which is an integrated measure of the deviation of all data points from the model predictions. This enables quantitative and statistical model comparisons for which all experiments and all data points together correspond to what would be called the 'group size' in a more classical statistical analysis. As different sources of data and experiments are combined in this analysis, it is not intuitive to express the number of independent experiments underlying this statistical analysis as *N* = x, but it should be noted that only the combined number of measured antagonist k~off~ values (17) and the observations of the cellular response of each antagonist at 10 different concentrations (17\*10 = 170) make clear that the data for our model has a large enough 'group size' to make reliable statistical comparisons between models. A schematic overview of the final model structure that was fitted to the cAMP response data (Model 1) is given in Figure [1](#bph14456-fig-0001){ref-type="fig"}.

###### 

Overview of the objective function values (OFVs) of the final model and the tested alternative models

  \#   Model                                    OFV       Model fit
  ---- ---------------------------------------- --------- ------------
  1    Final model                              62 404    Successful
  2    \+ PKA                                   62 411    Successful
  3    − inverse agonism (k~0~)                 102 215   Terminated
  4    − receptor recycling (RR)                81 594    Terminated
  5    \+ degradation of dopamine               62 404    Successful
  6    − active PDE degradation (k~5~)          62 307    Successful
  7    \+ assumption of fast binding kinetics   67 468    Successful

The changes compared to Model 1 are indicated by the mechanistic detail that was added (+) or removed (−) from Model 1.

![Schematic overview of the structure of the final model (Model 1) used for data fitting and simulations in this study. DA denotes dopamine, L denotes the antagonist, R denotes the D~2~‐receptor, RD denotes the D~2~‐receptor‐dopamine complex and RL denotes the receptor antagonist complex. RR indicates receptor recycling; the internalization (or degradation) of the dopamine‐receptor complex and the resurfacing (or synthesis) of the unbound receptor and dopamine. Black arrows denote mass transfer, green arrows an activating interaction and red arrows an inhibiting interaction. The equations of Model 1 are given in [Supporting Information Data S3](#bph14456-supitem-0003){ref-type="supplementary-material"}.](BPH-175-4121-g001){#bph14456-fig-0001}

Frequency response analysis: simulations of the predicted *in vivo* response to fluctuating dopamine concentrations {#bph14456-sec-0013}
-------------------------------------------------------------------------------------------------------------------

Dopamine concentrations were varied over time according to a sine wave with various frequencies, a mean concentration of 20 nM and an amplitude of 10 nM. The applied antagonist concentration was 14 nM and the antagonist K~D~ was 6.9 nM. The LFR~50~ was 1.03, and all system‐specific parameters were identical to Table [3](#bph14456-tbl-0003){ref-type="table"}. The dopamine fluctuations induce fluctuations in the cAMP concentrations, but the amplitude of these fluctuations is dependent on the frequency of the dopamine fluctuations. To get a complete analysis of the cAMP response to fluctuating dopamine concentrations in the presence of an antagonist and to cover all physiologically relevant frequencies (Young *et al*., [1998](#bph14456-bib-0056){ref-type="ref"}; Schultz, [2007](#bph14456-bib-0044){ref-type="ref"}; Vauquelin *et al*., [2012](#bph14456-bib-0052){ref-type="ref"}), a wide frequency range was tested between 2\*10^−6^ min^−1^ and 7 min^−1^. The simulated frequencies were 0.002, 0.007, 0.02, 0.07, 0.2, 0.7, 2, 7, 20, 70, 200, 700, 2000 and 7000\*10^−3^ min^−1^. The simulations were run for 6000 min plus 25\* the period of the dopamine fluctuations, to ensure a stable steady state was reached. For frequencies higher than 1 min^−1^, a step size parameter and absolute tolerance were added to the lsoda solver, to avoid model instability. As the step size parameter, the period of the dopamine fluctuations was divided by 400 and as absolute tolerance, a value of 10^−6^ was used to ensure better model stability at the higher frequencies. The initial values of the differential equations were set to the approximated steady‐state values as given in [Supporting Information Data S5.](#bph14456-supitem-0005){ref-type="supplementary-material"}

###### 

Estimates for the system‐specific parameters and their uncertainties from fitting Model 1 to the cAMP response data

  Parameter                       Value (unit)           RSE (%)
  ------------------------------- ---------------------- ------------------------------
  K~D~ dopamine                   10.3 (nM)              4.0
  k~off~ dopamine                 1.69 (min^−1^)         Input parameter
  DAFR~50~                        2.25                   2.4
  R~tot~                          1.74 (nM)              1.3
  RR                              0.238 (min^−1^)        2.2
  k~0max~                         20.5 (AU·min^−1^)      0.50
  k~1~                            4.12 (AU·min^−1^)      0.80
  k~2~ (active PDE‐independent)   0.0334 (min^−1^)       11
  k~3~ (active PDE‐dependent)     0.00882 (nM·min^−1^)   0.20
  k~4~                            0.00882 (min^−1^)      Defined as identical to k~3~
  k~5~                            0.0005 (min^−1^)       Input parameter
  h                               1.77                   0.40

Naming of the parameters corresponds to Figure [1](#bph14456-fig-0001){ref-type="fig"}. DAFR~50~ denotes the ratio of the total receptor concentration divided by the dopamine‐bound receptor concentration that inhibits the maximal cAMP synthesis to 50%; R~tot~ denotes the total receptor concentration; k~0max~ denotes the maximal value of k~0~; h denotes the hill factor of the non‐linear relationship between D~2~‐receptor occupancy and cAMP synthesis (k~0~). The dopamine k~off~ was based on the *in vitro* measurements, and the chosen values for k~4~ and k~5~ are described in the text. RSE, relative standard error; AU, arbitrary units.

After the cAMP concentration had reached constant fluctuation around the average steady state (i.e. the mean of the minimal and maximal concentration), the amplitudes of both the dopamine and the cAMP concentrations were converted to amplitudes relative to their average steady state values, and their ratio was defined as the 'cAMP gain', according to Equation [(1)](#bph14456-disp-0001){ref-type="disp-formula"}. This gain is a measure for the degree to which dopamine fluctuations results in cAMP fluctuations, and thus, the degree to which a biological signal encaptured in dopamine fluctuations is transduced. All simulations were performed in Rstudio using the deSolve package and the lsoda differential equation solving method (Soetaert *et al*., [2010](#bph14456-bib-0046){ref-type="ref"}; R Core Team, [2013](#bph14456-bib-0037){ref-type="ref"}). $$\textit{Gain\ cAMP} = \frac{\frac{\textit{amplitude\ cAMP}\ }{\textit{average\ steady\ state\ cAMP}}}{\frac{\textit{amplitude\ dopamine}\ }{\textit{average\ steady\ state\ dopamine}}}.$$

Materials {#bph14456-sec-0014}
---------

Janssen Pharmaceutica (Beerse, Belgium) supplied clozapine, dopamine, forskolin, JNJ‐37822681, JNJ‐39269646, haloperidol, olanzapine, paliperidone and ziprasidone. Sigma‐Aldrich supplied domperidone, dopamine, pimozide, quetiapine, S‐(+)‐raclopride, risperidone and sertindole. MolPort, (Riga, Latvia) supplied remoxipride and spiperone. Toronto Research Chemicals, Inc., (North York, Canada) supplied bromperidol and (‐)‐nemonapride.

Nomenclature of targets and ligands {#bph14456-sec-0015}
-----------------------------------

Key protein targets and ligands in this article are hyperlinked to corresponding entries in <http://www.guidetopharmacology.org>, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding *et al*., [2018](#bph14456-bib-0020){ref-type="ref"}), and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander *et al*., [2017a](#bph14456-bib-0001){ref-type="ref"},[b](#bph14456-bib-0002){ref-type="ref"}).

Results {#bph14456-sec-0016}
=======

*In vitro* measurements of target binding and signal transduction kinetics {#bph14456-sec-0017}
--------------------------------------------------------------------------

We have used a novel TR‐FRET based assay technology to measure the K~D~, k~on~ and k~off~ values of 17 dopamine D~2~ receptor antagonists at both room temperature and 37°C. Two datasets were generated using fluorescent derivatives of a fast agonist (PPHT) and a slower antagonist (spiperone). In general, there was a good correlation of the results obtained with both tracers (Supporting Information Figure [S1](#bph14456-supitem-0001){ref-type="supplementary-material"}f). Only the PPHT dataset was used to develop the models presented here, since this faster tracer allows the determination of a wider range of rate constants. The results (shown in Figure [2](#bph14456-fig-0002){ref-type="fig"}, Table [1](#bph14456-tbl-0001){ref-type="table"}, [Supporting Information Table S1 and Supporting Information Table S2](#bph14456-supitem-0001){ref-type="supplementary-material"}) are in good agreement with previously published reports that used radioligand binding, as shown in Supporting Information Figure [S1](#bph14456-supitem-0001){ref-type="supplementary-material"}f (Leysen and Gommeren, [1986](#bph14456-bib-0031){ref-type="ref"}; Freedman *et al*., [1994](#bph14456-bib-0018){ref-type="ref"}; Toll *et al*., [1998](#bph14456-bib-0050){ref-type="ref"}; Seeman and Tallerico, [1998](#bph14456-bib-0045){ref-type="ref"}; Kapur and Seeman, [2000](#bph14456-bib-0022){ref-type="ref"}; Richelson and Souder, [2000](#bph14456-bib-0038){ref-type="ref"}; Kongsamut *et al*., [2002](#bph14456-bib-0027){ref-type="ref"}; Kroeze *et al*., [2003](#bph14456-bib-0028){ref-type="ref"}; Burstein *et al*., [2005](#bph14456-bib-0005){ref-type="ref"}; Langlois *et al*., [2012](#bph14456-bib-0030){ref-type="ref"}; Wood *et al*., [2015](#bph14456-bib-0054){ref-type="ref"}; Klein Herenbrink *et al*., [2016](#bph14456-bib-0025){ref-type="ref"}). Figure [2](#bph14456-fig-0002){ref-type="fig"} shows that the D~2~ receptor antagonists evaluated in this study had diverse combinations of k~on~ and k~off~ values and that none of them had a combined low k~on~ and low k~off~ value.

![*In vitro* measurements of k~on~ and k~off~ for each of the measured D~2~ antagonists as obtained at room temperature using the kPCA assay. The numbers refer to the compound numbers in Table [1](#bph14456-tbl-0001){ref-type="table"}. The diagonal lines indicate constant affinities.](BPH-175-4121-g002){#bph14456-fig-0002}

For compounds with higher dissociation rates than the competing fluorescent ligand (k~off~ ≥ 0.01 s^−1^), the precision of the k~off~ estimates is lower, and in some cases, only the lower limit could be identified. However, for the experiments and model fits in this study, the exact value of the k~off~ has less influence on the cAMP concentration for fast compared to slow dissociating compounds and a low precision for high k~off~ values is thus acceptable for the scope of this study. Moreover, it should be noted that for practical reasons, the binding parameters are estimated as mean and SDs. This assumes a normal distribution, which can extend to negative numbers. To prevent this, estimation of geometric mean and geometric SD would have been more appropriate. This assumption only makes a difference where a significant part of the assumed normal distribution is negative, which again is mainly the case for the fast dissociating compounds for which the exact value of the k~off~ is less influential on model performance.

Our cAMP and DMR measurement provide a new and extensive set of signal transduction data for 17 D~2~ receptor antagonists. Figure [3](#bph14456-fig-0003){ref-type="fig"} shows the measured cAMP concentrations during the complete time course of a typical experiment with‐ and a control experiment without dopamine D~2~‐receptor transfection. For comparison, the DMR responses are given in [Supporting Information Data S2](#bph14456-supitem-0002){ref-type="supplementary-material"}. In Figure [4](#bph14456-fig-0004){ref-type="fig"}, the complete set of measured cAMP time courses for all 17 D~2~ receptor antagonists at 10 different concentrations is given, together with their model fits. The data in Figure [4](#bph14456-fig-0004){ref-type="fig"} show that the antagonists with lower k~off~ values (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=90>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=965>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=94>) induce cAMP concentration‐time curves for the lower antagonist concentrations with later and lower peak concentrations, compared to faster dissociating compounds (JNJ‐39269646, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=38>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=47>). In other words, for the slower dissociating compounds, a more pronounced increase in the time to reach maximal cAMP concentrations with decreasing antagonist concentrations is observed compared to faster dissociating antagonists. However, this trend was not observed in the DMR data (see [Supporting Information Data S2](#bph14456-supitem-0002){ref-type="supplementary-material"}).

![Observed cAMP response during a typical experiment of the Glo‐sensor cAMP assay. The red arrows indicate addition of Glo‐substrate, forskolin, dopamine and the tested ligand. The green data points were measured in wild type CHO cells, while the blue data points were measured in CHO cells transfected with the dopamine D~2~‐receptor. *N* = 1 for CHO/WT, *N* = 4 for CHO/D~2~. RLU, relative light units.](BPH-175-4121-g003){#bph14456-fig-0003}

![Model fits for all *in vitro* cAMP data as measured in transfected CHO cells. Both the observed (dots) and model‐predicted (lines) cAMP signals are included. The colours correspond to the applied concentration in each experiment. The top‐left panel shows the cAMP measurements and model predictions for the first 60 min in between forskolin addition and antagonist addition. The lower panels only show the time points after antagonist addition. Each dot represents a single measurement for which *n* = 1; for each concentration and each time point, three measurements are included. The numbers in the panel labels are the k~off~ values in min^−1^ as used for the model fits for each antagonist.](BPH-175-4121-g004){#bph14456-fig-0004}

Model‐based analysis of the *in vitro* cAMP antagonist response curves {#bph14456-sec-0018}
----------------------------------------------------------------------

### Model selection {#bph14456-sec-0019}

A series of related model structures, which differed in mechanistic detail, was evaluated for their utility to describe the cAMP responses (Table [2](#bph14456-tbl-0002){ref-type="table"}). From these models, Model 1 was selected as the final one for further analyses. This model selection was based on the lowest OFV and on the goodness of fit, as described in [Methods](#bph14456-sec-0006){ref-type="sec"} section. In Model 1, all antagonists also functioned as inverse agonists by stimulating cAMP production (see Figure [1](#bph14456-fig-0001){ref-type="fig"}), and the inverse agonism efficacy was estimated by the model for each antagonist. Model 1 was compared with alternative models to ensure that Model 1 was the optimal model.

Model 2 incorporated more mechanistic detail compared to Model 1 by including the role of <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=284> in linking the cAMP concentrations to active PDE concentrations. The performance of Model 2 was identical to the performance of the simpler Model 1. In addition, the estimated value of PKA turnover was high compared to cAMP and active PDE turnover, which means that the PKA addition to the model did not introduce any further delay in the response kinetics.

Models 3 and 4 were simplified models compared to Model 1 that excluded inverse agonism and receptor recycling respectively. Models 3 and 4 clearly performed worse than Model 1, as indicated by the much higher OFVs.

Model 5 included dopamine elimination/degradation, but this did not improve the model fit.

Model 6 used a fixed value for k~5~ which was set to 0. This model performed slightly (although highly significant: *P* \< 1\*10^−9^) better than Model 1. The value of k~5~ (0.0005 min^−1^) in the final model (Model 1) was chosen for a combination of physiological and numerical reasons: setting k~5~ to zero as in Model 6 would mean that active PDE is only synthesized and not degraded, which would result in a physiologically implausible infinite increase in active PDE concentrations. Moreover, all other parameter values than k~5~ differed maximally 5% between Model 6 and Model 1.

Finally, Model 7 demonstrates the contribution of slow binding kinetics to the model fit of the final model, as the exclusion of slow binding kinetics (k~off~ was set to 10 min^−1^ for all antagonists in Model 7) resulted in a large increase of the OFV (*P* \< 1\*10^−9^), compared to Model 1.

### Model fitting {#bph14456-sec-0020}

The model fits of Model 1 in Figure [4](#bph14456-fig-0004){ref-type="fig"} demonstrate that the general shape of the cAMP concentration‐time curve and the concentration‐dependency of the antagonist effect on the cAMP concentration are well captured by the model for all compounds. The equations of Model 1 are given in [Supporting Information Data S3](#bph14456-supitem-0003){ref-type="supplementary-material"}. For a few compounds (i.e. clozapine, bromperidol), the peak cAMP concentration or the cAMP concentrations in the terminal phase for the highest antagonist concentrations are underpredicted. The parameter estimates that were the same for all antagonists are given in Table [3](#bph14456-tbl-0003){ref-type="table"}, and all parameter estimates are given in [Supporting Information Data S3 and Table S3](#bph14456-supitem-0003){ref-type="supplementary-material"}. The uncertainty in the parameter estimates is low, as indicated by the small residual standard errors.

Frequency response analysis: simulations of the predicted *in vivo* response to fluctuating dopamine concentrations {#bph14456-sec-0021}
-------------------------------------------------------------------------------------------------------------------

The simulations of the response to fluctuating dopamine concentrations resulted in a fluctuation pattern of cAMP over time for each dopamine fluctuation frequency that was tested. The cAMP fluctuation amplitude was dependent on the frequency, as illustrated in Figure [5](#bph14456-fig-0005){ref-type="fig"}.

![Examples of simulations for low (left‐hand plots) and high (right‐hand plots) frequency fluctuations of dopamine concentrations. The dashed lines indicate the average steady state values of the fluctuations, which are calculated as the mean of the maximal and the minimal concentrations. Note the different time scales on the left compared to the right plots. The antagonist k~off~ was 2.5 min^−1^ for these simulations.](BPH-175-4121-g005){#bph14456-fig-0005}

From these dopamine and cAMP fluctuations, the relative amplitudes and the ratio of these relative amplitudes could be calculated to obtain the cAMP gain (Equation [(1)](#bph14456-disp-0001){ref-type="disp-formula"}, see [Methods](#bph14456-sec-0006){ref-type="sec"} section) as illustrated in Figure [6](#bph14456-fig-0006){ref-type="fig"}. The two simulations in Figures [5](#bph14456-fig-0005){ref-type="fig"} and [6](#bph14456-fig-0006){ref-type="fig"} thus provide two points on the line for an antagonist k~off~ of 2.5 min^−1^ in the graph of Figure [7](#bph14456-fig-0007){ref-type="fig"}; at a frequency of 2 × 10^−5^ min^−1^ and 2 min^−1^, the cAMP gain is 0.36 and 0.0080 respectively. For a more detailed explanation, see Supporting Information Data [S4](#bph14456-supitem-0004){ref-type="supplementary-material"}. The cAMP gain that is obtained by this method is an indication of the extent to which fluctuations in dopamine concentrations lead to fluctuations in cAMP concentrations. By doing so, the cAMP gain informs on the role of dopamine fluctuations on dopamine signalling. A low cAMP gain (cAMP gain \<\< 1) indicates that only the average dopamine concentrations and not the dopamine fluctuations determine cAMP levels, while a high cAMP gain (cAMP gain ≈ 1) indicates that both the average dopamine concentrations and the dopamine fluctuations determine cAMP levels.

![Comparison of relative dopamine and cAMP fluctuations (converted from concentration fluctuations) with average steady state values. The δ sign refers to the difference between the concentration and the average steady state concentration. From these data, the gain can be identified according to Equation [(1)](#bph14456-disp-0001){ref-type="disp-formula"}, which is approximately 0.36 for the left‐hand plots and 0.0080 for the right‐hand plots. The antagonist k~off~ was 2.5 min^−1^ for these simulations.](BPH-175-4121-g006){#bph14456-fig-0006}

![Frequency response analysis of the relative amplitude of cAMP fluctuations normalized to the relative amplitude of dopamine fluctuations (gain). The frequency on the *x*‐axes denotes the frequency of the dopamine concentration sine wave that has been used as input for the simulations. The different colours represent different dissociation rate constants (k~off~) for the antagonist. The applied antagonist concentration was 14 nM while the antagonist K~D~ was 6.9 nM for all simulations in both plots. The applied dopamine concentrations had a median value of 20 nM and an amplitude of 10 nM. The value of k~on~ changed simultaneously with k~off~ such that the K~D~ was constant. The dashed lines indicate characteristic frequencies for the red line (k~off~ = 0.004 min^−1^) at which the gain increases (cf~1~) and decreases (cf~2~) to new plateau values and decreases linearly with increasing frequencies (cf~3~).](BPH-175-4121-g007){#bph14456-fig-0007}

From the frequency response analysis as shown in Figure [7](#bph14456-fig-0007){ref-type="fig"}, the following was observed:

If dopamine fluctuations occur slowly, the cAMP response has a steady gain (i.e. the cAMP fluctuations have a constant amplitude) for frequencies lower than 1\*10^−5^ min^−1^ in Figure [7](#bph14456-fig-0007){ref-type="fig"}. This gain is increased for intermediate frequencies (between 1\*10^−4^ and 0.1 min^−1^) and decreases steeply for higher frequencies. The influence of drug‐target binding kinetics on the transduction of dopamine fluctuations into cAMP fluctuations is limited to intermediate frequencies between 1\*10^−4^ and 0.1 min^−1^ of dopamine fluctuations.

The model‐based frequency response analysis allowed characterization of the cAMP response to a wide range of dopamine fluctuation frequencies (as shown in Figure [7](#bph14456-fig-0007){ref-type="fig"}). This analysis identified the influence of each model parameter on the cAMP response. The cAMP gain versus dopamine fluctuation frequency graphs as shown in Figure [7](#bph14456-fig-0007){ref-type="fig"} are dependent on the antagonist k~off~ and can have up to three characteristic frequencies around which the gain changes. The positions of the characteristic frequencies are dependent on the parameter values, as discussed below, and have been derived empirically from the gain versus frequency plot as the frequencies at which the cAMP gain starts to change. These frequencies were numbered cf~1~, cf~2~ and cf~3~, as indicated in Figure [7](#bph14456-fig-0007){ref-type="fig"}. From the lowest dopamine fluctuation frequencies to cf~1~, the cAMP gain is independent of the antagonist k~off~ and does not change with increasing frequency, until cf~1~ is reached where the gain increases towards a new plateau value. The frequency at which the cAMP gain declines to a new plateau value, cf~2~, is dependent on the antagonist k~off~ and cannot be observed for high‐k~off~ antagonists, which is shown for k~off~ values between 0.5 and 2.5 min^−1^ (Figure [7](#bph14456-fig-0007){ref-type="fig"}). The third characteristic frequency, cf~3~, is independent of the antagonist k~off~ and introduces a decline in the cAMP gain that is linear with the increasing frequency.

The influence of the model parameters on the characteristic frequencies was identified by repeating the FRA for different values of each model parameter, as shown in [Supporting Information Data S5](#bph14456-supitem-0005){ref-type="supplementary-material"}. As illustrated by Supporting Information Figure [S5](#bph14456-supitem-0005){ref-type="supplementary-material"}, the value of cf~1~ depends on the value of the active PDE turnover rate constant k~5~. This can be understood by considering that the increase in cAMP gain is caused by a reduced negative feedback if the turnover of active PDE is too slow, relative to the fast fluctuations of cAMP. The second characteristic frequency, cf~2~, is influenced by the antagonist k~off~ and by the antagonist concentration, as illustrated in [Supporting Information Figure S8](#bph14456-supitem-0005){ref-type="supplementary-material"}. The role of the antagonist k~off~ can be explained by the slow displacement of antagonists with a low k~off~ value and the consequently reduced fluctuation of dopamine receptor occupancy. The role of the antagonist concentration can be explained by the higher antagonist receptor occupancy and the relatively lower influence of fluctuating dopamine concentrations on the antagonist receptor occupancy for higher antagonist concentrations. The third characteristic frequency, cf~3~, is determined by both the cAMP turnover and the dopamine k~off~, as shown in [Supporting Information Figures S6 and S7](#bph14456-supitem-0005){ref-type="supplementary-material"} respectively. These parameters determine the turnover of cAMP and dopamine receptor occupancy, respectively, and the slowest turnover is thus rate limiting for the eventual turnover of cAMP and the maximal frequency of dopamine fluctuations that can be translated into cAMP fluctuations without a declining fluctuation amplitude. In summary, if k~5~ (active PDE turnover) increases, cf~1~ increases, if the antagonist concentration or k~off~ increases, cf~2~ increases and if k~3~ (cAMP turnover) increases, cf~3~ increases.

Overall, the translation of fluctuating dopamine concentrations into fluctuation of cAMP concentrations is inhibited to a larger extent by antagonists with a low k~off~ value compared to antagonists with a high k~off~ value. However, this role of the antagonist k~off~ is only present if the dopamine fluctuation frequency is not too high (i.e. higher than cf~3~) to be translated and not too slow (i.e. lower than cf~2~) to be able to displace even a slow dissociating antagonist.

Discussion {#bph14456-sec-0022}
==========

In this study, we developed a minimal mechanistic model that describes the cellular effects of dopamine D~2~ receptor antagonism on cAMP turnover, including dopamine and antagonist receptor binding kinetics as well as active PDE turnover. The model was able to describe successfully *in vitro* binding and cAMP concentration‐time profiles data obtained for 17 D~2~ receptor antagonists. Compared to fast dissociating antagonists, slowly dissociating D~2~ receptor antagonists lead to a reduced response to fluctuating dopamine concentrations as previously suggested in the fast‐off hypothesis (see below) for dopamine antagonists. However, this influence of antagonist binding kinetics is only observed to antagonists with a lower k~off~ value than 0.5 min^−1^ and to dopamine fluctuation frequencies higher than the antagonist k~off~ and lower than 0.5 min^−1^. This range is determined by the cAMP turnover, the dopamine k~off~ and the antagonist k~off~.

Insight into the influence of target binding kinetics on dopamine D ~2~ receptor antagonism {#bph14456-sec-0023}
-------------------------------------------------------------------------------------------

According to the fast‐off hypothesis for dopamine D~2~ receptor antagonists, extrapyramidal side effects can be avoided if dopamine can displace these antagonists from the receptor (Kapur and Seeman, [2001](#bph14456-bib-0023){ref-type="ref"}). According to this hypothesis, the k~off~ of an antagonist needs to be high enough to allow that fast fluctuations of dopamine concentration result in the same effects in terms of dopamine D~2~‐receptor occupancy. However, this hypothesis is only theoretically true under two conditions: (i) fast fluctuations of dopamine receptor occupancy are relevant for the downstream effects of dopamine signalling and (ii) fast fluctuations of dopamine concentrations result in fast fluctuations of dopamine receptor occupancy, if there is no competition for receptor binding. In this study, we demonstrate that both conditions apply for a limited range of dopamine fluctuation frequencies and k~off~ values. Moreover, this study also suggests that the influence of the antagonist k~off~ is of limited extent at therapeutically relevant antagonist occupancies of 60--80%. In fact, fluctuations of endogenous signalling molecules can function as an efficient transduction of the intensity of a constant biological signal, a concept known as frequency encoding. In this case, the average concentration is determining the signal transduction instead of the fluctuations in the signalling molecule concentration. When the fluctuations of dopamine concentrations are not determining the signal transduction, the influence of the antagonist k~off~ on dopamine receptor occupancy fluctuations is unlikely to be relevant for the efficacy or safety of the antagonist. *In vivo*, dopamine concentrations fluctuate with different frequencies. In a dopaminergic synapse, the fastest dopamine fluctuations occur within milliseconds, while slower fluctuations also occur upon activation and deactivation and extra‐synaptically (Schultz, [2007](#bph14456-bib-0044){ref-type="ref"}). To find out which frequencies of the *in vivo* fluctuations in dopamine concentration can be transduced into cAMP fluctuations, and what is the influence of the antagonist k~off~ thereon, we used simulations to obtain the cAMP gain (i.e. the extent to which dopamine concentration fluctuations are transduced into cAMP concentration fluctuations). To this end, we first obtained a consistent set of parameter values from *in vitro* cAMP response measurements to describe the most important kinetic processes between dopamine fluctuations and cAMP fluctuations.

The k~off~ values that would be necessary for the displacement of dopamine according to the fast‐off hypothesis were analysed previously (Vauquelin *et al*., [2012](#bph14456-bib-0052){ref-type="ref"}), but the kinetics of signal transduction were not taken into account in that study. Here, we show that the displacement of D~2~ receptor antagonists by dopamine is not generating a fluctuating response if the frequency of fluctuation in D~2~ receptor occupancy is higher than what the endogenous signal transduction can translate into a cellular signal, such as cAMP fluctuation. In this study, it is indicated that the rate of endogenous signal transduction is limited both by the dopamine k~off~ and by the cAMP turnover. This can be understood by realizing that each process (antagonist binding, dopamine binding, cAMP turnover) can act as a delay between dopamine concentration fluctuations and cAMP concentration fluctuations, as illustrated in [Supporting Information Data S5](#bph14456-supitem-0005){ref-type="supplementary-material"}. This delay attenuates the fluctuations if it is longer than the fluctuation frequency. When this delay is already induced by dopamine binding or cAMP turnover, there is no additional delay imposed by slow antagonist binding, as long as the antagonist binding is faster than dopamine binding and cAMP turnover. Therefore, signal transduction needs to be taken into account to study the influence of binding kinetics on the time course of the drug effect. Our results should not be interpreted as evidence against the relation between D~2~ receptor antagonist binding kinetics for their safety profile but as evidence for additional value of signal transduction kinetics, which are not included in the fast‐off hypothesis to explain this relationship. It should be noted that alternatives for the fast‐off hypothesis are available to explain the difference in extrapyramidal side effects between D~2~ receptor antagonists, including the serotonin hypothesis. (Meltzer, [1999](#bph14456-bib-0033){ref-type="ref"})

Extrapolation of *in vitro* to *in vivo* antagonism and signal transduction {#bph14456-sec-0024}
---------------------------------------------------------------------------

This study reveals how the relevance of the D~2~ receptor antagonist k~off~ depends on the kinetics of signal transduction and negative feedback. In addition, our study provides new insight into the translation of different dopamine fluctuation frequencies into downstream signalling. We speculate that these insights could be used to develop more selective drug treatments towards high or low frequency signalling, for example, for synaptic versus extra‐synaptic antagonism. Interestingly, Sykes *et al*. recently demonstrated that a correlation between k~off~ and EPS could not be identified, while a correlation with k~on~ (and probably K~D~) could be identified (Sykes *et al*., [2017](#bph14456-bib-0049){ref-type="ref"}). On the other hand, a correlation between k~off~ and the effect on prolactin could be identified. While EPS is believed to originate in the neurological synapse, the prolactin response originates in the lactotroph. The differential correlation with k~off~ could therefore also be related with slower dopamine fluctuations in the lactotroph, compared to the synapse. Although we provide a quantitative estimate of the maximal value of k~off~ that could decrease the inhibited transduction of dopamine fluctuations, it should be noted that this value cannot be translated directly into the *in vivo* situation.

Firstly, the temperature at which the signal transduction experiments were performed, room temperature, is not physiological, and most reactions (including drug‐target binding kinetics) will be faster at 37°C. However, the difference in binding kinetics between these temperatures is moderate, although highly variable: the ratio of the k~off~ values for the measured D~2~ antagonists in this study at 37°C divided by the k~off~ at room temperature was 3.2‐fold on average and between 0.10 and 7.4 in the whole dataset, while for k~on~, this ratio was 2.7 on average and between 0.038 and 6.5 (see [Supporting Information Data S1](#bph14456-supitem-0001){ref-type="supplementary-material"}). Therefore, we expect that the kinetics of signal transduction will be different at 37°C compared to our measurements at room temperature. While we do not expect differences of more than one order of magnitude, we cannot exclude larger differences. Although the rate constant of the various kinetic processes might be different *in vivo*, our analysis also identified the role of each rate constant and can thus be used to understand and analyse the *in vivo* situation as well.

Secondly, the analysis of Model 1 in this study only incorporates signal transduction into cAMP and active PDE levels, while in the clinical *in vivo* situation, more transduction steps are involved before the antipsychotic effect of D~2~ receptor antagonists is obtained. The differences between the time curves of cAMP and the cellular OD, as measured by DMR ([Supporting Information Data S2](#bph14456-supitem-0002){ref-type="supplementary-material"}), provide a first indication of possible differences between the cAMP response and downstream signalling, but the mechanistic interpretation of cellular OD requires more advanced experimental designs (Schröder *et al*., [2010](#bph14456-bib-0042){ref-type="ref"}).

Thirdly, the analysis of the cAMP response data with Models 1--7 is not sufficient to obtain a conclusive and comprehensive description of the mechanism(s) underlying the observed cAMP responses. Although various mechanisms were represented by Models 1--7 and fitted to the data, some of these models provide similar fits (e.g. Model 1 and Model 5), and the true mechanism cannot be identified based on these fits alone. To get a better insight into the role of each parameter, we have performed a sensitivity analysis and included the results in [Supporting Information Data S5](#bph14456-supitem-0005){ref-type="supplementary-material"}. This shows the identical sensitivity of k~3~ and k~4~, which explains that these parameters could not be estimated separately. It should be noted that the influence of each parameter as shown in this figure only demonstrates the influence of each parameter if all other parameters have their standard value, which prevents drawing general conclusions of parameter identifiability. Also, the transfected CHO cells used in the *in vitro* measurements of CAMP are not brain cells, and the system‐specific parameter values as obtained by the model fit in this study might therefore be different from the *in vivo* situation.

All of these factors might explain why the receptor recycling rate constant as identified here (0.238 min^−1^) does not correspond to previous more direct estimates of the D~2~‐receptor degradation rate constant from rat striatum (0.0001 min^−1^) (Zou *et al*., [1996](#bph14456-bib-0058){ref-type="ref"}; Dewar *et al*., [1997](#bph14456-bib-0013){ref-type="ref"}). Moreover, our estimate for the dopamine K~D~ of 10 nM indicates a dominant high‐affinity state of the D~2~‐receptor in the cellular system used for cAMP measurements rather than a dominant low‐affinity state which were previously determined as 6.1 and 3650 nM respectively (Durdagi *et al*., [2015](#bph14456-bib-0014){ref-type="ref"}). Although this high affinity seems to be close to the *in vivo* affinity (Richfield *et al*., [1989](#bph14456-bib-0039){ref-type="ref"}; Flietstra and Levant, [1998](#bph14456-bib-0016){ref-type="ref"}), others have found much lower dopamine affinities in CHO cell lines, in agreement with our kPCA results (Sokoloff *et al*., [1990](#bph14456-bib-0047){ref-type="ref"}; Freedman *et al*., [1994](#bph14456-bib-0018){ref-type="ref"}). This difference might be induced by the experimental conditions during the cAMP experiment, such as the addition of forskolin or the required level of receptor expression, which do not need to be present if the experimental goal is only the measurement of the K~D~. Moreover, the K~D~ values as determined in this study in the kPCA experiments are in the same order of magnitude as those recently published by Sykes *et al*. ([2017](#bph14456-bib-0049){ref-type="ref"}), although their values are on average around twofold lower than ours, which might be related to the addition of guanine in their experiments. In general, our focus on cAMP signalling and the influence of the experimental conditions prevent from drawing direct conclusions about the influence of D~2~‐receptor antagonist binding kinetics on *in vivo* extrapyramidal side effects. However, the critical elements in the structure of Model 1 are well supported by previous studies: inverse agonism has been reported for many of the D~2~ receptor antagonists as described in [Introduction](#bph14456-sec-0005){ref-type="sec"} section (Hall and Strange, [1997](#bph14456-bib-0019){ref-type="ref"}; Bond and IJzerman, [2006](#bph14456-bib-0004){ref-type="ref"}). The active PDE‐independent degradation of cAMP has been described before in a more extensive GPCR signalling model (Violin *et al*., [2008](#bph14456-bib-0053){ref-type="ref"}) and is also supported by the different molecules that can hydrolyze cAMP (Cherry and Pho, [2002](#bph14456-bib-0007){ref-type="ref"}; Keravis and Lugnier, [2012](#bph14456-bib-0024){ref-type="ref"}). The two cAMP production rate constants represent the constitutive receptor activity, which is inhibited by inverse agonism (de Ligt *et al*., [2000](#bph14456-bib-0011){ref-type="ref"}) and the remaining cAMP production.

Finally, the frequency response analysis that was used here is based on a sine‐wave function while the dopamine fluctuations in the brain occur with a more variable frequency and amplitude (Schultz, [2007](#bph14456-bib-0044){ref-type="ref"}; Vauquelin *et al*., [2012](#bph14456-bib-0052){ref-type="ref"}).

The absolute limit of the influence of binding kinetics on antagonist effects cannot be translated directly into *in vivo* situations, but our findings demonstrate that such a limitation is likely to exist *in vivo* as well and may be expected to be in the order of minutes. Although we focus on extrapyramidal side effects, according to the fast‐off hypothesis, these side effects are caused by a dopamine signalling inhibition that is too strong, blocking too much dopamine signalling. Our findings for EPS are thus directly linked to antipsychotic action, if this is mainly mediated by inhibition of dopaminergic signalling. These results indicate that sub‐second dopamine fluctuations possibly cannot be translated into cAMP fluctuations and that sub‐second k~off~ values might not be required to minimize extrapyramidal side effects. This also questions that antagonists with sub‐second dissociation half‐lives yield different inhibition of dopamine signalling compared to antagonists with dissociation half‐lives in the second‐minute range, as suggested before based on theoretical considerations (Vauquelin *et al*., [2012](#bph14456-bib-0052){ref-type="ref"}). The relevance of these results are supported by the parameters that were identified to be most influential, the dopamine k~off~ and the cAMP degradation rate constant, which are unlikely to be affected by experimental design.

We have shown that for a common transduction system including an indirect effect and a negative feedback loop, the relevance of fast drug‐target dissociation can be limited by the target dissociation of the endogenous ligand and the turnover of the second messenger. The rate constants for dopamine dissociation from the D~2~‐receptor and cAMP turnover that we have obtained in this study indicate the relevance of signal transduction kinetics for D~2~ receptor antagonists. Our study demonstrates that the influence of target binding kinetics on drug effects cannot be fully understood without taking into account signal transduction and feedback kinetics, especially if fluctuating endogenous ligand concentrations are present.

In conclusion, the cellular cAMP response to dopamine D~2~ receptor antagonists could be described using a minimal mechanistic model including *in vitro* measured dopamine and antagonist D~2~ binding kinetics, in conjunction with synthesis and degradation of cAMP and active PDE. This model revealed that slowly dissociating D~2~ receptor antagonists show a reduced transduction of dopamine fluctuations into cAMP fluctuations, compared to fast dissociating antagonists. However, this influence of the dissociation rate constant is limited to dopamine fluctuations that are faster than the k~off~ value of the drug but slower than the dopamine k~off~ value and the cAMP turnover. In general, we conclude that the influence of drug‐target binding kinetics on drug effect kinetics is dependent on the dynamics of signal transduction kinetics and that both the turnover of second messengers and the k~off~ value of endogenous ligands might limit the discrimination between fast and slowly dissociating antagonists.
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**Data S1** Measurements of binding kinetics and equilibrium binding for antagonists at room temperature and at 37°C.

**Table S1** Affinity and kinetic parameters derived from binding equilibrium (ePCA) and binding kinetics (kPCA) measurements. Values represent the mean of two independent experiments with two replicates each (*N* = 2, *n* = 2) at 37°C. NA: only one independent experiment could be evaluated. ND: steady state affinities were beyond the concentration range tested or kinetic traces did not fit to the models used for evaluation.

**Table S2** Affinity and kinetic parameters derived from binding equilibrium (ePCA) and binding kinetics (kPCA) measurements. Values represent the mean of two independent experiments with two replicates each (*N* = 2, *n* = 2) at room temperature. NA: only one independent experiment could be evaluated. ND: binding data did not fit to the models used for evaluation.

**Figure S1** Determination of affinity and kinetic parameters for the binding of Dopamine D~2~‐receptor drugs using the TagLite^®^ homogeneous time resolved fluorescence (HTRF) technology and the equilibrium and kinetic Probe Competition Assays (ePCA and kPCA). Symbols represent the measured data and lines the fits to the corresponding binding models. The compounds indicated with fastD2 and fastD2bu refer to JNJ‐37822681 and JNJ‐39269646, respectively. (A) Characterization of the PPHT tracer used in ePCA and kPCA at room temperature and at 37°C. The upper panel shows representative steady state titration curves, and the lower panel kinetic association‐ and dissociation curves at increasing tracer concentrations. HTRF signals were fit to the models specified in the methods section and the resulting binding parameters are indicated in the graphs. The data shown correspond to a single experiment with three replicates. Tracer input parameters used to compute the binding constants of test compounds were averaged from two independent experiments with three replicates each. (B‐C) Representative kPCA traces (corresponding to a single experiment with two replicates) of the compounds listed in Table S1 at room temperature (b) and 37°C (c). Compound names are indicated on top of the graphs, Dosing is indicated by the color code specified on the right‐hand side. (D‐E) ePCA dose‐response curves of the compounds listed in Table S1 at room temperature (d) and 37°C (e). Compound names are indicated on top of the graphs The different symbols represent different dilution series. Data shown represent the average of two independent experiment with two replicates each. (F) Comparison of the binding parameters obtained with PPHT‐based tracer (agonist) and Spiperone‐based tracer (antagonist). (G) Comparison of the binding parameters shown in Tables S1 and S2 with literature data. Reference numbers correspond to the following literature sources: 1 = (Kapur and Seeman, 2000), 2 = (Kroeze *et al*., 2003), 3 = (Burstein *et al*., 2005), 4 = (Langlois *et al*., 2012), 5 = (Kongsamut *et al*., 2002), 6 = (Toll *et al*., 1998), 7 = (Freedman *et al*., 1994), 8 = (Richelson and Souder, 2000), 9 = (Seeman and Tallerico, 1998), 11 = (Leysen and Gommeren, 1986).
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Click here for additional data file.

###### 

**Data S2** DMR experimental overview and results for all D~2~ antagonists.

**Figure S2** Example of the complete DMR versus time curve for 10 μM haloperidol. The time points of addition of dopamine and the ligand (haloperidol in this case) are indicated with the red arrows.

**Figure S3** Normalized Dynamic Mass Redistribution (DMR) responses as change in DMR response in picometer compared to the dopamine response after addition of various concentrations of the indicated antagonists. Normalization was performed by subtracting the response per well/replicate at the latest time point after dopamine addition and before antagonist addition (t = 31 min) from the raw DMR traces. Normalization for the dopamine + buffer was performed for each time point by subtracting the mean dopamine + buffer in each experiment/well plate from the normalized DMR traces.
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Click here for additional data file.
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**Data S3** Model 1 equations and parameter estimates for all dopamine D~2~ antagonists.

**Table S3** Parameter estimates from fitting the final model to the cAMP response data. Asterisks indicate parameter values that were not estimated but used as input parameter values. DAFR~50~ denotes the ratio of the total receptor concentration divided by the dopamine‐bound bound receptor concentration that inhibits the cAMP synthesis to 50%, LFR~50~ denotes the ratio of the total receptor concentration divided by the antagonist bound receptor concentration that generates the halfmaximal antagonist‐dependent cAMP synthesis (i.e. k~0~ equals 0.5 \* k~0max~), R~tot~ denotes the total receptor concentration, k0max denotes the maximal value of k~0~.
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**Data S4** Explanation of frequency response analysis results (FRA)

**Figure S4** Example of input frequencies for dopamine as used in the simulations (top panels) and the simulated responses (lower panels). The second row shows the dopamine receptor occupancy, the third row the antagonist receptor occupancy and the bottom row the cAMP response for each simulation with the fluctuating dopamine concentrations from the corresponding top row panels. The different line colors represent different simulations for which the dissociation rate constant of the antagonist‐receptor complex is changed. The dopamine fluctuation frequencies are indicated above the panels and by the different time scales on the x‐axis.
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**Data S5** Identification of the influence of system‐specific parameters on the frequency response analysis results.

**Figure S5** Frequency response analysis for 3 different active PDE turnover rate constants and 5 different antagonist k~off~ values. The upper plots show the influence of the antagonist k~off~ for two different active PDE turnover rate constants, and the lower plots show the influence of the active PDE turnover rate constant for two different k~off~ values. The input signal was a sine wave of free dopamine with an amplitude of 10nM and baseline of 20 nM, at the frequencies indicated on the x‐axis. At each active PDE turnover rate, 5 different antagonist k~off~ values were simulated, which are represented by the different line colors. The k~on~ values were changed simultaneously with k~off~, which means that the K~D~ was constant at 6.93 nM. The antagonist concentration was 14 nM, the LFR~50~ was 1.03 and all system‐specific parameters were identical to Table 3.

**Figure S6** Frequency response analysis for 5 active PDE‐dependent cAMP turnover rate constant (k~3~) values and 5 antagonist k~off~ values. The upper plots show the influence of the antagonist k~off~ for two different active PDE turnover rate constants, and the lower plots show the influence of the active PDE‐dependen cAMP turnover rate constant for two different k~off~ values. The input signal was a sine wave of free dopamine with an amplitude of 10nM and baseline of 20 nM, at the frequencies indicated on the x‐axis. At each cAMP turnover rate, 5 different antagonist k~off~ values were simulated, which are represented by the different line colors. The k~on~ values were changed simultaneously with k~off~, which means that the K~D~ was constant at 6.93 nM. The antagonist concentration was 14 nM, the LFR~50~ was 1.03 and all system‐specific parameters were identical to Table 3.

**Figure S7** Frequency response analysis for 4 different dopamine‐receptor k~off~ values and 5 different antagonist k~off~ values. The upper plots show the influence of the antagonist k~off~ for two different active PDE turnover rate constants, and the lower plots show the influence of the dopamine k~off~ for two different antagonist k~off~ values. The input signal was a sine wave of free dopamine with an amplitude of 10nM and baseline of 20 nM, at the frequencies indicated on the x‐axis. At each dopamine dissociation rate constant, 5 different antagonist k~off~ values were simulated, which are represented by the different line colors. The k~on~ values were changed simultaneously with k~off~, which means that the K~D~ was constant at 6.93 nM. The antagonist concentration was 14 nM, the LFR~50~ was 1.03 the receptor recycling rate constant was switched to 0 and all other system‐specific parameters were identical to Table 3.

**Figure S8** Frequency response analysis for 4 different antagonist concentrations and 5 different antagonist k~off~ values. The upper plots show the influence of the antagonist k~off~ for two different active PDE turnover rate constants, and the lower plots show the influence of the antagonist concentration for two different antagonist k~off~ values. The input signal was a sine wave of free dopamine with an amplitude of 10nM and baseline of 20 nM, at the frequencies indicated on the xaxis. At each antagonist concentration, 5 different antagonist k~off~ values were simulated, which are represented by the different line colors. The k~on~ values were changed simultaneously with k~off~, which means that the KD was constant at 6.93 nM. The antagonist concentration was 14 nM, the LFR50 was 1.03 and all system‐specific parameters were identical to Table 3.

**Figure S9** Sensitivity analysis for 5 different antagonist concentrations (line colours) and for a 10‐fold increase and decrease of each parameter from Table 3, the antagonist K~D~, k~off~ and the LFR~50~ (panels). The middle panels are the same in the whole figure, representing the parameters in Table 3, an antagonist K~D~ value of 6.93 nM, an antagonist k~off~ value of 0.1 min^‐1^ and an LFR~50~ value of 1.02. The y‐axis can change between the different panels.
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